STTR Phase I: Assessing an innovative Microfluidic Tissue Array device for applications in drug development and precision medicine

STTR 第一阶段：评估创新的微流控组织阵列设备在药物开发和精准医疗中的应用

• 批准号: 1938430
• 负责人: Lian Wang
• 金额: $ 22.47万
• 依托单位: Vivoz Biolabs LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-01-01 至 2022-03-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1938430&HistoricalAwards=false
• 关键词: STTR; Phase; Assessing; innovative; Microfluidic

The broader/commercial impact of this project aims to develop and commercialize a microfluidic device as a clinical platform to rapidly identify precise and effective therapies for individual cancer patients. Currently, prediction in precision medicine only has limited success, and the American Society of Clinical Oncology (ASCO) does not recommend using any specific drug sensitivity testing method alone to guide clinical treatment decision-making. Therefore, there is an urgent and unmet clinical need to create a rapidly implementable and clinically relevant experimental system that can rapidly and economically test the effects of therapeutic options on an individual patient's biopsy. The microfluidic platform developed in this project aims to rapidly and accurately evaluate drug efficacy using individual patient's biopsies, thus guiding personalized cancer treatment and leading to increased survival rates, reduced cost of healthcare, and improved quality of patient life. In addition, this technology will facilitate cancer drug discovery and development in terms of cost and time, leading to reduced costs of drug development. This Small Business Technology Transfer (STTR) Phase I project will develop a microfluidic system that preserves viability, structure, and other biological properties of tissue biopsy samples, providing a platform for efficient drug screening and determining the responsiveness of individual patient cancer samples to therapeutic drugs. Current precision medicine for cancer treatment is mainly prediction-based on cancer genomic data instead of direct test or validation of the responsiveness of patient cancer samples to drugs. Lack of rapid and accurate methods for such direct tests is a major obstacle in cancer treatment. To overcome this obstacle, Microfluidic Tissue Arrays (µFTA) will be developed to mimic physiological blood perfusion to maintain the native microenvironment of tumor samples. As a result, tumor tissues cultured in the µFTAs can preserve their in vivo biological properties. This project will establish the feasibility of setting up a robust assay in the µFTA for measuring tumor tissue response to drugs and assess initial correlation of the obtained data with in vivo results. The ultimate goal of this project is to develop a µFTA-based platform to directly evaluate the responsiveness of patient biopsy tissues to different therapies, thus providing drug selection guidance for individual patients.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该项目的更广泛/商业影响旨在开发和商业化微流控设备作为临床平台，以快速识别针对个体癌症患者的精确有效疗法。目前，精准医学中的预测仅取得了有限的成功，美国临床肿瘤学会（ASCO）不建议单独使用任何特定的药物敏感性测试方法来指导临床治疗决策。因此，迫切且未满足的临床需要是创建可快速实施且临床相关的实验系统，其可以快速且经济地测试治疗选项对个体患者的活检的影响。该项目开发的微流体平台旨在使用个体患者的活检快速准确地评估药物疗效，从而指导个性化癌症治疗，提高生存率，降低医疗成本，提高患者生活质量。此外，该技术将在成本和时间方面促进癌症药物的发现和开发，从而降低药物开发成本。该小企业技术转让（STTR）第一阶段项目将开发一种微流体系统，该系统可保留组织活检样本的活力，结构和其他生物学特性，为有效的药物筛选和确定个体患者癌症样本对治疗药物的反应性提供平台。目前用于癌症治疗的精准医学主要是基于癌症基因组数据的预测，而不是直接测试或验证患者癌症样本对药物的反应性。缺乏快速准确的直接检测方法是癌症治疗的主要障碍。为了克服这一障碍，将开发微流控组织阵列（µFTA）来模拟生理血液灌注，以维持肿瘤样本的天然微环境。因此，在µ FTA中培养的肿瘤组织可以保持其体内生物学特性。该项目将确定在µFTA中建立一种用于测量肿瘤组织对药物的反应的稳健检测方法的可行性，并评估所获得的数据与体内结果的初步相关性。该项目的最终目标是开发一个基于µ FTA的平台，直接评估患者活检组织对不同疗法的反应性，从而为个体患者提供药物选择指导。该奖项反映了NSF的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。